The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)

被引：0
|
作者：
Yilmaz, Musa [1 ]
Kantarjian, Hagop M. [2 ]
Ravandi, Farhad [2 ]
Jorgensen, Jeffrey L. [3 ]
Wang, Sa [3 ]
Garcia-Manero, Guillermo [2 ]
Cortes, Jorge E. [2 ]
Sasaki, Koji [2 ]
DiNardo, Courtney [2 ]
Kadia, Tapan [2 ]
Autry, Jane [2 ]
Garris, Rebecca [2 ]
Jabbour, Elias [2 ]
机构：
[1] Baylor Coll Med, Dept Hematol & Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Differential Impact of Minimal Residual Disease Negativity According to the Salvage Status in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Jabbour, Elias
    Short, Nicholas J.
    Jorgensen, Jeffrey L.
    Yilmaz, Musa
    Ravandi, Farhad
    Wang, Sa A.
    Thomas, Deborah A.
    Khoury, Joseph
    Champlin, Richard E.
    Khouri, Issa
    Kebriaei, Partow
    O'Brien, Susan M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Sasaki, Koji
    Dinardo, Courtney D.
    Kadia, Tapan M.
    Jain, Nitin
    Konopleva, Marina
    Garris, Rebecca
    Kantarjian, Hagop M.
    CANCER, 2017, 123 (02) : 294 - 302
  • [2] Prognostic Impact of Full Hematologic Recovery and Achievement of Measurable Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) After First Salvage Therapy
    Rafei, Hind
    Ravandi, Farhad
    Hwang, Hyunsoo
    Ning, Jing
    Cortes, Jorge
    Kadia, Tapan
    DiNardo, Courtney
    Jabbour, Elias
    Daver, Naval
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Issa, Ghayas
    Kantarjian, Hagop
    Short, Nicholas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S218 - S219
  • [3] CNCT19 for Treatment of Patients with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-cell ALL) in Children and Adults
    Wang, Ying
    Chen, Xiaojuan
    Wei, Shuning
    Mi, Yingchang
    Shi, Lin
    Wang, Ying
    Wang, Yongzeng
    Haudenschild, Changting
    Lv, Lulu
    Zhu, Xiaofan
    Wang, Jianxiang
    BLOOD, 2021, 138
  • [4] Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy
    Short, Nicholas J.
    Rafei, Hind
    Daver, Naval G.
    Hwang, Hyunsoo
    Ning, Jing
    Cortes, Jorge E.
    Jorgensen, Jeffrey L.
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Wang, Sa A.
    Jabbour, Elias
    Popat, Uday
    Oran, Betul
    Konopleva, Marina Y.
    Garcia-Manero, Guillermo
    Borthakur, Gautam M.
    Bhalla, Kapil N.
    Issa, Ghayas C.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    BLOOD, 2019, 134
  • [5] CLINICAL PHARMACOLOGY CHARACTERIZATION OF BLINATUMOMAB FROM SUBCUTANEOUS (SC) DOSING IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
    Wong, H.
    Chandra, F.
    Zugmaier, G.
    Gordon, P.
    Penny, H.
    Doshi, S.
    Upreti, V.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S82 - S83
  • [6] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure
    Dahl, Jenny
    Kantarjian, Hagop M.
    Yilmaz, Musa
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge E.
    Ferrajoli, Alessandra
    Sasaki, Koji
    Chahoud, Jad
    Autry, Jane
    Garris, Rebecca
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [8] Inotuzumab Ozogamicin (Besponsa®) for Patients with relapsed or refractory acute lymphoblastic Leukemia (r/r ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 66 - 66
  • [9] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali
    Rodriguez, Vilmarie
    O'Brien, Maureen Megan
    McNeer, Jennifer Lynn
    Loh, Mignon L.
    Rheingold, Susan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] TIME AND COST OF HOSPITALIZATION FOR SALVAGE THERAPY AMONG ADULTS WITH PHILADELHPHIA (PH)-NEGATIVE B-CELL RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN SPAIN
    Boluda, B.
    Rodriguez-Veiga, R.
    Martinez-Cuadron, D.
    Lorenzo, L.
    Sanz, G.
    Sanz, J.
    Regadera, A.
    Sempere, A.
    Senent, L.
    Cervera, J.
    Reitan, J.
    Gea, S.
    Sanz, M.
    Montesinos, P.
    VALUE IN HEALTH, 2016, 19 (07) : A726 - A726
12345